Ascendis Pharma regains full rights to its TransCon platform in cardiometabolic indications following the end of its Novo Nordisk collaboration.
Ascendis Pharma to regain TransCon rights in metabolic diseases
Ascendis Pharma will reclaim full rights to its TransCon platform in cardiometabolic indications after ending its Novo Nordisk collaboration.
biotech.disruptsmedia.com
September 30, 2026 at 4:00 PM
Ascendis Pharma regains full rights to its TransCon platform in cardiometabolic indications following the end of its Novo Nordisk collaboration.
Turns out….was macht denn Fritz-kola da?
February 21, 2026 at 8:54 PM
Turns out….was macht denn Fritz-kola da?
Awesome! ASCENDIS PHARMA A/S just raised DKK 716,261 at a valuation of DKK 50,062,684,561 (https://www.enhjorning.bot/company/29918791).
September 29, 2026 at 9:33 AM
Awesome! ASCENDIS PHARMA A/S just raised DKK 716,261 at a valuation of DKK 50,062,684,561 (https://www.enhjorning.bot/company/29918791).
🚨 $BMRN
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). The terms of the Agreement are consistent with those contained in the binding term sheet previously entered into by the parti...
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). The terms of the Agreement are consistent with those contained in the binding term sheet previously entered into by the parti...
SEC Filing: BMRN
Click to view the official SEC document.
www.sec.gov
September 30, 2026 at 8:18 PM
🚨 $BMRN
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). The terms of the Agreement are consistent with those contained in the binding term sheet previously entered into by the parti...
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). The terms of the Agreement are consistent with those contained in the binding term sheet previously entered into by the parti...
Danish connection: $ASND collaboration with $NVO for TransCon tech in metabolic and cardiovascular disease
$285M upfront
investors.ascendispharma.com/news-release...
$285M upfront
investors.ascendispharma.com/news-release...
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases | Ascendis Pharma
investors.ascendispharma.com
November 4, 2024 at 1:34 PM
Danish connection: $ASND collaboration with $NVO for TransCon tech in metabolic and cardiovascular disease
$285M upfront
investors.ascendispharma.com/news-release...
$285M upfront
investors.ascendispharma.com/news-release...
PANTHERx® Rare Teams Up with Ascendis Pharma for YORVIPATH® Distribution#United_States#Pittsburgh#YORVIPATH®#Ascendis_Pharma#PANTHERx
PANTHERx® Rare Teams Up with Ascendis Pharma for YORVIPATH® Distribution
PANTHERx® Rare partners with Ascendis Pharma to distribute YORVIPATH®, a treatment for hypoparathyroidism, providing vital support for patients nationwide.
third-news.com
December 6, 2024 at 6:19 PM
PANTHERx® Rare Teams Up with Ascendis Pharma for YORVIPATH® Distribution#United_States#Pittsburgh#YORVIPATH®#Ascendis_Pharma#PANTHERx
JPMorgan raises its target price on Ascendis Pharma to $300 from $295.
August 18, 2026 at 2:54 AM
JPMorgan raises its target price on Ascendis Pharma to $300 from $295.
🔥 Hot design opportunity!
Join the innovative team at Ascendis Pharma as a UX Designer in Copenhagen, Denmark. Work on projects that challenge and inspire.
Apply now: https://uiuxjobsboard.com/job/1215825-ux-designer-copenhagen-denmark
#uxdesign #jobs #tech
Join the innovative team at Ascendis Pharma as a UX Designer in Copenhagen, Denmark. Work on projects that challenge and inspire.
Apply now: https://uiuxjobsboard.com/job/1215825-ux-designer-copenhagen-denmark
#uxdesign #jobs #tech
UX Designer at Ascendis Pharma in Copenhagen Denmark
Ascendis Pharma is hiring a UX Designer in Copenhagen Denmark (September 2025). Are you passionate about getting medicine to patients? Do you have experien
uiuxjobsboard.com
September 14, 2025 at 6:01 PM
🔥 Hot design opportunity!
Join the innovative team at Ascendis Pharma as a UX Designer in Copenhagen, Denmark. Work on projects that challenge and inspire.
Apply now: https://uiuxjobsboard.com/job/1215825-ux-designer-copenhagen-denmark
#uxdesign #jobs #tech
Join the innovative team at Ascendis Pharma as a UX Designer in Copenhagen, Denmark. Work on projects that challenge and inspire.
Apply now: https://uiuxjobsboard.com/job/1215825-ux-designer-copenhagen-denmark
#uxdesign #jobs #tech
#VerantwortungUndKonsequenz
Beitrag 9 - Sponsoren des CDU-Parteitags 2026
Im Februar fand der 38. Parteitag der CDU statt. Diverse Firmen und Lobbyverbände unterstützten als Sponsor, u.a.
Firmen:
Abbvie
Amazon
Ascendis
Bayer
Telekom
Sparkassen
DHL
EnBW
Enpal
Evonik
EWE
fritz-kola
FUTRUE
👉
Beitrag 9 - Sponsoren des CDU-Parteitags 2026
Im Februar fand der 38. Parteitag der CDU statt. Diverse Firmen und Lobbyverbände unterstützten als Sponsor, u.a.
Firmen:
Abbvie
Amazon
Ascendis
Bayer
Telekom
Sparkassen
DHL
EnBW
Enpal
Evonik
EWE
fritz-kola
FUTRUE
👉
March 25, 2026 at 8:47 AM
#VerantwortungUndKonsequenz
Beitrag 9 - Sponsoren des CDU-Parteitags 2026
Im Februar fand der 38. Parteitag der CDU statt. Diverse Firmen und Lobbyverbände unterstützten als Sponsor, u.a.
Firmen:
Abbvie
Amazon
Ascendis
Bayer
Telekom
Sparkassen
DHL
EnBW
Enpal
Evonik
EWE
fritz-kola
FUTRUE
👉
Beitrag 9 - Sponsoren des CDU-Parteitags 2026
Im Februar fand der 38. Parteitag der CDU statt. Diverse Firmen und Lobbyverbände unterstützten als Sponsor, u.a.
Firmen:
Abbvie
Amazon
Ascendis
Bayer
Telekom
Sparkassen
DHL
EnBW
Enpal
Evonik
EWE
fritz-kola
FUTRUE
👉
Novo Nordisk announced yesterday that they're partnering with another Danish company, Ascendis Pharma, on $ASND's TransCon platform to potentially develop a once monthly GLP-1 receptor agonist for obesity & Type 2 diabetes investors.ascendispharma.com/news-release... #biosky
November 5, 2024 at 12:27 PM
Novo Nordisk announced yesterday that they're partnering with another Danish company, Ascendis Pharma, on $ASND's TransCon platform to potentially develop a once monthly GLP-1 receptor agonist for obesity & Type 2 diabetes investors.ascendispharma.com/news-release... #biosky
The @fda.gov has approved once-weekly #Navepegritide for children aged 2 years or older with #Achondroplasia, according to an announcement from Ascendis Pharma.
Read more: https://bit.ly/4cr1IGz
#RareDisease #MedSky
Read more: https://bit.ly/4cr1IGz
#RareDisease #MedSky
Once-Weekly Navepegritide Approved for Children With Achondroplasia Aged 2 or Older
The US Food and Drug Administration has approved once-weekly navepegritide for children aged 2 years or older with achondroplasia.
bit.ly
March 4, 2026 at 6:06 PM
The @fda.gov has approved once-weekly #Navepegritide for children aged 2 years or older with #Achondroplasia, according to an announcement from Ascendis Pharma.
Read more: https://bit.ly/4cr1IGz
#RareDisease #MedSky
Read more: https://bit.ly/4cr1IGz
#RareDisease #MedSky
#ASND YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
https://www.stocktitan.net/news/ASND/yorvipath-palopegteriparatide-now-commercially-available-in-the-sem6k6agrdrg.html
https://www.stocktitan.net/news/ASND/yorvipath-palopegteriparatide-now-commercially-available-in-the-sem6k6agrdrg.html
Ascendis Pharma Launches First-Ever FDA-Approved Treatment for Adult Hypoparathyroidism in US
YORVIPATH, a groundbreaking once-daily therapy, marks a historic milestone as the first FDA-approved medicine for adult hypoparathyroidism patients in the United States.
www.stocktitan.net
December 19, 2024 at 1:30 PM
#ASND YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
https://www.stocktitan.net/news/ASND/yorvipath-palopegteriparatide-now-commercially-available-in-the-sem6k6agrdrg.html
https://www.stocktitan.net/news/ASND/yorvipath-palopegteriparatide-now-commercially-available-in-the-sem6k6agrdrg.html
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two | ...
www.fiercebiotech.com
September 19, 2026 at 1:39 PM
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
Ascendis will present infant achondroplasia data from its navepegritide pivotal trial at ESPE 2026. Early cohort results from reACHin.
Ascendis to present infant achondroplasia data at ESPE 2026
Ascendis Pharma will share sentinel cohort data from its reACHin pivotal trial of navepegritide in infants under two at ESPE 2026.
biotech.disruptsmedia.com
September 16, 2026 at 8:00 AM
Ascendis will present infant achondroplasia data from its navepegritide pivotal trial at ESPE 2026. Early cohort results from reACHin.
Signal or noise? > Novo walks away from $285M pact to develop monthly GLP-1
obesity drug with Ascendis >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #competitivemarketing #pharmaceutical
obesity drug with Ascendis >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #competitivemarketing #pharmaceutical
Novo walks away from $285M pact to develop monthly GLP-1
obesity drug with Ascendis
Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two years.
dlvr.it
September 15, 2026 at 10:58 AM
Signal or noise? > Novo walks away from $285M pact to develop monthly GLP-1
obesity drug with Ascendis >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #competitivemarketing #pharmaceutical
obesity drug with Ascendis >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #competitivemarketing #pharmaceutical
Ascendis and BioMarin have settled their YUVIWEL dispute. Ascendis will pay BioMarin royalties up to 20% on navepegritide net sales through May 2030, ending all litigation between the companies.
Ascendis and BioMarin settle YUVIWEL dispute with royalty deal
Ascendis Pharma will pay BioMarin royalties of up to 20% on navepegritide net sales through May 2030 to resolve all litigation between the two companies.
biotech.disruptsmedia.com
September 11, 2026 at 4:00 PM
Ascendis and BioMarin have settled their YUVIWEL dispute. Ascendis will pay BioMarin royalties up to 20% on navepegritide net sales through May 2030, ending all litigation between the companies.
Ascendis reports 52-week data for navepegritide in infant achondroplasia: foramen magnum stenosis stabilised, linear growth improved. Early signal in a condition with few treatment options.
Ascendis Pharma reports 52-week infant data for TransCon CNP at ESPE
Week 52 sentinel cohort data show navepegritide stabilised foramen magnum stenosis and improved linear growth in infants with achondroplasia.
biotech.disruptsmedia.com
September 10, 2026 at 10:36 AM
Ascendis reports 52-week data for navepegritide in infant achondroplasia: foramen magnum stenosis stabilised, linear growth improved. Early signal in a condition with few treatment options.